Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2025-06-10 Declaration of Voting R…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 10 JUNE 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of poll voting results at the company's Annual General Meeting, listing the resolutions and vote counts. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2025-06-10 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATIONS ON THE STUDY RESULTS OF ORAL SMALL MOLECULE GLP-1R AGONIST ASC30 AND ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE ASC
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement under Hong Kong Exchange rules announcing scientific poster presentations at the ADA conference. It contains no financial results, no management changes, no capital actions, no voting or governance materials, and is not an investor slide deck. It is a general business update and does not fit any specific category, so it defaults to the Regulatory Filings (RNS) fallback.
2025-06-09 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES PHASE III TRIAL OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR FOR ACNE, MEETS ALL ENDPOINTS
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Ascletis Pharma Inc. detailing Phase III clinical trial topline results for their acne drug Denifanstat. It is not a financial report (10-K/IR/ER), governance or management change notice, capital/financing update, dividend notice, M&A announcement, or other specific category. It provides operational R&D information and is filed as a general regulatory announcement on the Hong Kong Exchange. The appropriate fallback classification is Regulatory Filings (RNS).
2025-06-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX Listing Rule monthly return (Form FF301) detailing movements in share capital, issued shares, treasury shares, and share option schemes for the month ended 31 May 2025. It is a regulatory compliance submission under Chapter 19B and not an annual or interim report, earnings release, management announcement, or other specific filing type. Therefore, it falls under the fallback category of general regulatory filings.
2025-06-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 May 2025
Share Issue/Capital Change Classification · 1% confidence The document is HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” detailing movements in authorised share capital, issued shares, treasury shares, share options and confirmations under the Listing Rules. This is not an annual or interim financial report but a regulatory submission specifically covering equity issuer capital changes. It therefore fits the Share Issue/Capital Change category (SHA).
2025-06-03 English
INSIDE INFORMATION - FINAL JUDGMENT ON LEGAL PROCEEDINGS INVOLVING ASC41 AND ASC43F
Legal Proceedings Report Classification · 1% confidence The document is an announcement by a Hong Kong listed company about the final judgment in ongoing legal proceedings (ITC ruling and sanctions) involving its drug candidates. It cites specific legal actions, is filed under the Listing Rules as inside information, and clearly updates shareholders on material legal issues. This matches the definition of a Legal Proceedings Report (LTR).
2025-05-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.